Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Christine Brideau

Christine Brideau is a Vice President, Preclinical Pharmacology, Deerfield Discovery and Development, and joined the Firm in 2019. Prior to Deerfield, Ms. Brideau was Vice President of In Vitro Pharmacology at WuXi AppTec and led the development of WuXi’s US-based in vitro biology unit in New Jersey. Before WuXi, Ms. Brideau spent 24 years at Merck, where she most recently served as Executive Director of In Vitro Pharmacology and supported multiple drug discovery projects from hit-to-lead to clinical candidate. She is the co-author of more than 40 peer-reviewed publications in the areas of pharmacology, assay development, screening day analysis, automation and compound management. Ms. Brideau is currently an editorial board member of SLAS Discovery and has served as a reviewer for the NIH Molecular Libraries Program study section.